Search

Your search keyword '"Fairlamb, Alan H."' showing total 693 results
Start Over Author "Fairlamb, Alan H."
693 results on '"Fairlamb, Alan H."'

1. Author Correction: Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis

Author

Wyllie, Susan, Thomas, Michael, Patterson, Stephen, Crouch, Sabrinia, De Rycker, Manu, Lowe, Rhiannon, Gresham, Stephanie, Urbaniak, Michael D., Otto, Thomas D., Stojanovski, Laste, Simeons, Frederick R. C., Manthri, Sujatha, MacLean, Lorna M., Zuccotto, Fabio, Homeyer, Nadine, Pflaumer, Hannah, Boesche, Markus, Sastry, Lalitha, Connolly, Paul, Albrecht, Sebastian, Berriman, Matt, Drewes, Gerard, Gray, David W., Ghidelli-Disse, Sonja, Dixon, Susan, Fiandor, Jose M., Wyatt, Paul G., Ferguson, Michael A. J., Fairlamb, Alan H., Miles, Timothy J., Read, Kevin D., and Gilbert, Ian H.

Published
2023
Full Text
View/download PDF

2. Sterol 14-alpha demethylase (CYP51) activity in Leishmania donovani is likely dependent upon cytochrome P450 reductase 1.

Author

Tulloch, Lindsay B., Tinti, Michele, Wall, Richard J., Weidt, Stefan K., Corpas- Lopez, Victoriano, Dey, Gourav, Smith, Terry K., Fairlamb, Alan H., Barrett, Michael P., and Wyllie, Susan

Subjects
CYTOCHROME P-450, LEISHMANIA donovani, DEMETHYLASE, VISCERAL leishmaniasis, AMPHOTERICIN B, PHYTOSTEROLS
Abstract

Liposomal amphotericin B is an important frontline drug for the treatment of visceral leishmaniasis, a neglected disease of poverty. The mechanism of action of amphotericin B (AmB) is thought to involve interaction with ergosterol and other ergostane sterols, resulting in disruption of the integrity and key functions of the plasma membrane. Emergence of clinically refractory isolates of L. donovani and L. infantum is an ongoing issue and knowledge of potential resistance mechanisms can help to alleviate this problem. Here we report the characterisation of four independently selected L. donovani clones that are resistant to AmB. Whole genome sequencing revealed that in three of the moderately resistant clones, resistance was due solely to the deletion of a gene encoding C24-sterol methyltransferase (SMT1). The fourth, hyper-resistant resistant clone (>60-fold) was found to have a 24 bp deletion in both alleles of a gene encoding a putative cytochrome P450 reductase (P450R1). Metabolic profiling indicated these parasites were virtually devoid of ergosterol (0.2% versus 18% of total sterols in wild-type) and had a marked accumulation of 14-methylfecosterol (75% versus 0.1% of total sterols in wild-type) and other 14-alpha methylcholestanes. These are substrates for sterol 14-alpha demethylase (CYP51) suggesting that this enzyme may be a bona fide P450R specifically involved in electron transfer from NADPH to CYP51 during catalysis. Deletion of P450R1 in wild-type cells phenocopied the metabolic changes observed in our AmB hyper-resistant clone as well as in CYP51 nulls. Likewise, addition of a wild type P450R1 gene restored sterol profiles to wild type. Our studies indicate that P450R1 is essential for L. donovani amastigote viability, thus loss of this gene is unlikely to be a driver of clinical resistance. Nevertheless, investigating the mechanisms underpinning AmB resistance in these cells provided insights that refine our understanding of the L. donovani sterol biosynthetic pathway. Author summary: The antifungal drug, amphotericin B, is also used in the treatment of visceral leishmaniasis, a potentially lethal parasitic disease infecting the specialised immune cells (macrophages) in the liver, spleen, and bone marrow. Treatment failures due to emerging drug resistance are a significant concern. Using a combination of genetic and biochemical approaches, we have confirmed the mechanisms by which these parasites become less sensitive to treatment with amphotericin B. In addition, we have identified a novel mechanism involving loss of a key enzyme (cytochrome P450 reductase 1) in the biosynthetic pathway to ergosterol, an important lipid component of the parasite's plasma membrane. These studies increase our fundamental understanding of this important metabolic pathway and provide information that may be exploited to develop novel therapeutic strategies to combat this killer disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties

Author

Fersing, Cyril, Boudot, Clotilde, Paoli-Lombardo, Romain, Primas, Nicolas, Pinault, Emilie, Hutter, Sébastien, Castera-Ducros, Caroline, Kabri, Youssef, Pedron, Julien, Bourgeade-Delmas, Sandra, Sournia-Saquet, Alix, Stigliani, Jean-Luc, Valentin, Alexis, Azqueta, Amaya, Muruzabal, Damián, Destere, Alexandre, Wyllie, Susan, Fairlamb, Alan H., Corvaisier, Sophie, Since, Marc, Malzert-Fréon, Aurélie, Di Giorgio, Carole, Rathelot, Pascal, Azas, Nadine, Courtioux, Bertrand, Vanelle, Patrice, and Verhaeghe, Pierre

Published
2020
Full Text
View/download PDF

5. Validation of Trypanosoma cruzi inactivation techniques for laboratory use.

Author

MacLean, Lorna M., Ariyanayagam, Mark, Sastry, Lalitha, Paterson, Christy, De Rycker, Manu, and Fairlamb, Alan H.

Subjects
TRYPANOSOMA cruzi, CHAGAS' disease, LIFE cycles (Biology), LABORATORY techniques, FREEZE-thaw cycles, PARASITIC diseases
Abstract

Trypanosoma cruzi (T. cruzi) is the causative agent of Chagas' disease, a parasitic infection responsible for significant morbidity and mortality in Latin America. The current treatments have many serious drawbacks and new drugs are urgently required. In the UK, T. cruzi is classified by the Advisory Committee on Dangerous Pathogens (ACDP) as a Hazard Group 3 organism and strict safety practices must be adhered to when handling this pathogen in the laboratory. Validated inactivation techniques are required for safe T. cruzi waste disposal and removal from Containment Level 3 (CL3) facilities for storage, transportation and experimental analysis. Here we assess three T. cruzi. inactivation methods. These include three freeze-thaw cycles, chemical inactivation with Virkon disinfectant, and air drying on Whatman FTA cards (A, B, C, Elute) and on a Mitra microsampling device. After each treatment parasite growth was monitored for 4–6 weeks by microscopic examination. Three freeze-thaw cycles were sufficient to inactivate all T. cruzi CLBrener Luc life cycle stages and Silvio x10/7 A1 large epimastigote cell pellets up to two grams wet weight. Virkon treatment for one hour inactivated T. cruzi Silvio x10/7 subclone A1 and CLBrener Luc both in whole blood and cell culture medium when incubated at a final concentration of 2.5% Virkon, or at ≥1% Virkon when in tenfold excess of sample volume. Air drying also inactivated T. cruzi CLBrener Luc spiked blood when dried on FTA A, B or Elute cards for ≥30 minutes and on a Mitra Microsampler for two hours. However, T. cruzi CLBrener Luc were not inactivated on FTA C cards when dried for up to two hours. These experimentally confirmed conditions provide three validated T. cruzi inactivation methods which can be applied to other related ACDP Hazard Group 2–3 kinetoplastid parasites. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. 8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi

Author

Fersing, Cyril, Boudot, Clotilde, Castera-Ducros, Caroline, Pinault, Emilie, Hutter, Sébastien, Paoli-Lombardo, Romain, Primas, Nicolas, Pedron, Julien, Seguy, Line, Bourgeade-Delmas, Sandra, Sournia-Saquet, Alix, Stigliani, Jean-Luc, Brossas, Jean-Yves, Paris, Luc, Valentin, Alexis, Wyllie, Susan, Fairlamb, Alan H., Boutet-Robinet, Élisa, Corvaisier, Sophie, Since, Marc, Malzert-Fréon, Aurélie, Destere, Alexandre, Mazier, Dominique, Rathelot, Pascal, Courtioux, Bertrand, Azas, Nadine, Verhaeghe, Pierre, and Vanelle, Patrice

Published
2020
Full Text
View/download PDF

7. Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

Author

Wyllie, Susan, Brand, Stephen, Thomas, Michael, De Rycker, Manu, Chung, Chun-wa, Pena, Imanol, Bingham, Ryan P., Bueren-Calabuig, Juan A., Cantizani, Juan, Cebrian, David, Craggs, Peter D., Ferguson, Liam, Goswami, Panchali, Hobrath, Judith, Howe, Jonathan, Jeacock, Laura, Ko, Eun-Jung, Korczynska, Justyna, MacLean, Lorna, Manthri, Sujatha, Martinez, Maria S., Mata-Cantero, Lydia, Moniz, Sonia, Nühs, Andrea, Osuna-Cabello, Maria, Pinto, Erika, Riley, Jennifer, Robinson, Sharon, Rowland, Paul, Simeons, Frederick R. C., Shishikura, Yoko, Spinks, Daniel, Stojanovski, Laste, Thomas, John, Thompson, Stephen, Gaza, Elisabet Viayna, Wall, Richard J., Zuccotto, Fabio, Horn, David, Ferguson, Michael A. J., Fairlamb, Alan H., Fiandor, Jose M., Martin, Julio, Gray, David W., Miles, Timothy J., Gilbert, Ian H., Read, Kevin D., Marco, Maria, and Wyatt, Paul G.

Published
2019

8. Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

Author

Baragan˜a, Beatriz, Forte, Barbara, Choi, Ryan, Hewitt, Stephen Nakazawa, Bueren-Calabuig, Juan A., Pisco, Joa˜o Pedro, Peet, Caroline, Dranow, David M., Robinson, David A., Jansen, Chimed, Norcross, Neil R., Vinayak, Sumiti, Anderson, Mark, Brooks, Carrie F., Cooper, Caitlin A., Damerow, Sebastian, Delves, Michael, Dowers, Karen, Duffy, James, Edwards, Thomas E., Hallyburton, Irene, Horst, Benjamin G., Hulverson, Matthew A., Ferguson, Liam, Jiménez-Díaz, María Belén, Jumani, Rajiv S., Lorimer, Donald D., Love, Melissa S., Maher, Steven, Matthews, Holly, McNamara, Case W., Miller, Peter, O’Neill, Sandra, Ojo, Kayode K., Osuna-Cabello, Maria, Pinto, Erika, Post, John, Riley, Jennifer, Rottmann, Matthias, Sanz, Laura M., Scullion, Paul, Sharma, Arvind, Shepherd, Sharon M., Shishikura, Yoko, Simeons, Frederick R. C., Stebbins, Erin E., Stojanovski, Laste, Straschil, Ursula, Tamaki, Fabio K., Tamjar, Jevgenia, Torrie, Leah S., Vantaux, Amélie, Witkowski, Benoît, Wittlin, Sergio, Yogavel, Manickam, Zuccotto, Fabio, Angulo-Barturen, Iñigo, Sinden, Robert, Baum, Jake, Gamo, Francisco-Javier, Mäser, Pascal, Kyle, Dennis E., Winzeler, Elizabeth A., Myler, Peter J., Wyatt, Paul G., Floyd, David, Matthews, David, Sharma, Amit, Striepen, Boris, Huston, Christopher D., Gray, David W., Fairlamb, Alan H., Pisliakov, Andrei V., Walpole, Chris, Read, Kevin D., Van Voorhis, Wesley C., and Gilbert, Ian H.

Published
2019

9. A novel multiple-stage antimalarial agent that inhibits protein synthesis

Author

Baragaña, Beatriz, Hallyburton, Irene, Lee, Marcus CS, Norcross, Neil R, Grimaldi, Raffaella, Otto, Thomas D, Proto, William R, Blagborough, Andrew M, Meister, Stephan, Wirjanata, Grennady, Ruecker, Andrea, Upton, Leanna M, Abraham, Tara S, Almeida, Mariana J, Pradhan, Anupam, Porzelle, Achim, Martínez, María Santos, Bolscher, Judith M, Woodland, Andrew, Luksch, Torsten, Norval, Suzanne, Zuccotto, Fabio, Thomas, John, Simeons, Frederick, Stojanovski, Laste, Osuna-Cabello, Maria, Brock, Paddy M, Churcher, Tom S, Sala, Katarzyna A, Zakutansky, Sara E, Jiménez-Díaz, María Belén, Sanz, Laura Maria, Riley, Jennifer, Basak, Rajshekhar, Campbell, Michael, Avery, Vicky M, Sauerwein, Robert W, Dechering, Koen J, Noviyanti, Rintis, Campo, Brice, Frearson, Julie A, Angulo-Barturen, Iñigo, Ferrer-Bazaga, Santiago, Gamo, Francisco Javier, Wyatt, Paul G, Leroy, Didier, Siegl, Peter, Delves, Michael J, Kyle, Dennis E, Wittlin, Sergio, Marfurt, Jutta, Price, Ric N, Sinden, Robert E, Winzeler, Elizabeth A, Charman, Susan A, Bebrevska, Lidiya, Gray, David W, Campbell, Simon, Fairlamb, Alan H, Willis, Paul A, Rayner, Julian C, Fidock, David A, Read, Kevin D, and Gilbert, Ian H

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Biotechnology, Infectious Diseases, Malaria, Orphan Drug, Vector-Borne Diseases, Rare Diseases, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Infection, Good Health and Well Being, Animals, Antimalarials, Drug Discovery, Female, Gene Expression Regulation, Life Cycle Stages, Liver, Male, Models, Molecular, Peptide Elongation Factor 2, Plasmodium, Plasmodium berghei, Plasmodium falciparum, Plasmodium vivax, Protein Biosynthesis, Quinolines, General Science & Technology
Abstract

There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and novel modes of action, to widen the scope of treatment and to overcome emerging drug resistance. Here we describe the discovery of DDD107498, a compound with a potent and novel spectrum of antimalarial activity against multiple life-cycle stages of the Plasmodium parasite, with good pharmacokinetic properties and an acceptable safety profile. DDD107498 demonstrates potential to address a variety of clinical needs, including single-dose treatment, transmission blocking and chemoprotection. DDD107498 was developed from a screening programme against blood-stage malaria parasites; its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis. This discovery of eEF2 as a viable antimalarial drug target opens up new possibilities for drug discovery.

Published
2015

11. The Genome of the African Trypanosome Trypanosoma brucei

Author

Berriman, Matthew, Ghedin, Elodie, Hertz-Fowler, Christiane, Blandin, Gaëlle, Renauld, Hubert, Bartholomeu, Daniella C., Lennard, Nicola J., Caler, Elisabet, Hamlin, Nancy E., Haas, Brian, Böhme, Ulrike, Hannick, Linda, Aslett, Martin A., Shallom, Joshua, Marcello, Lucio, Hou, Lihua, Wickstead, Bill, Arrowsmith, Claire, Atkin, Rebecca J., Barron, Andrew J., Bringaud, Frederic, Brooks, Karen, Carrington, Mark, Cherevach, Inna, Chillingworth, Tracey-Jane, Churcher, Carol, Clark, Louise N., Corton, Craig H., Cronin, Ann, Davies, Rob M., Doggett, Jonathon, Djikeng, Appolinaire, Feldblyum, Tamara, Field, Mark C., Fraser, Audrey, Goodhead, Ian, Hance, Zahra, Harper, David, Harris, Barbara R., Hauser, Heidi, Hostetler, Jessica, Ivens, Al, Jagels, Kay, Johnson, David, Johnson, Justin, Jones, Kristine, Kerhornou, Arnaud X., Koo, Hean, Larke, Natasha, Landfear, Scott, Larkin, Christopher, Leech, Vanessa, Line, Alexandra, Lord, Angela, MacLeod, Annette, Mooney, Paul J., Moule, Sharon, Morgan, Gareth W., Mungall, Karen, Norbertczak, Halina, Ormond, Doug, Pai, Grace, Peacock, Chris S., Peterson, Jeremy, Quail, Michael A., Rabbinowitsch, Ester, Rajandream, Marie-Adele, Reitter, Chris, Salzberg, Steven L., Sanders, Mandy, Schobel, Seth, Sharp, Sarah, Simmonds, Mark, Simpson, Anjana J., Tallon, Luke, Tait, Andrew, Tivey, Adrian R., Van Aken, Susan, Walker, Danielle, Wanless, David, Wang, Shiliang, White, Brian, White, Owen, Whitehead, Sally, Woodward, John, Wortman, Jennifer, Adams, Mark D., Embley, T. Martin, Gull, Keith, Ullu, Elisabetta, Barry, J. David, Fairlamb, Alan H., Opperdoes, Fred, Barrell, Barclay G., Donelson, John E., Hall, Neil, Fraser, Claire M., Melville, Sara E., and El-Sayed, Najib M.

Published
2005

16. Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis

Author

Wyllie, Susan, Thomas, Michael, Patterson, Stephen, Crouch, Sabrinia, De Rycker, Manu, Lowe, Rhiannon, Gresham, Stephanie, Urbaniak, Michael D., Otto, Thomas D., Stojanovski, Laste, Simeons, Frederick R. C., Manthri, Sujatha, MacLean, Lorna M., Zuccotto, Fabio, Homeyer, Nadine, Pflaumer, Hannah, Boesche, Markus, Sastry, Lalitha, Connolly, Paul, Albrecht, Sebastian, Berriman, Matt, Drewes, Gerard, Gray, David W., Ghidelli-Disse, Sonja, Dixon, Susan, Fiandor, Jose M., Wyatt, Paul G., Ferguson, Michael A. J., Fairlamb, Alan H., Miles, Timothy J., Read, Kevin D., and Gilbert, Ian H.

Published
2018
Full Text
View/download PDF

25. Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases

Author

Calderón, Felix, primary, Ballell, Lluis, additional, Barros, David, additional, Bilbe, Graeme, additional, Cammack, Nicholas, additional, Gabarró, Raquel, additional, Halsey, Audra, additional, Heaton, Penny M., additional, Kang, Gagandeep, additional, Mizrahi, Valerie, additional, Nathan, Carl, additional, Strange, Mike E., additional, Williams, Pauline M., additional, Winzeler, Elizabeth A., additional, and Fairlamb, Alan H., additional

Published
2021
Full Text
View/download PDF

27. Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity

Author

Pacheco, Juliana da Silva, primary, Costa, Débora de Souza, additional, Cunha-Júnior, Edézio Ferreira, additional, Andrade-Neto, Valter Viana, additional, Fairlamb, Alan H., additional, Wyllie, Susan, additional, Goulart, Marília O. F., additional, Santos, Danyelle C., additional, Silva, Thaissa L., additional, Alves, Marina A., additional, Costa, Paulo R. R., additional, Dias, Ayres G., additional, and Torres-Santos, Eduardo Caio, additional

Published
2021
Full Text
View/download PDF

28. 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase

Author

Zani Carlos L and Fairlamb Alan H

Subjects
trypanothione reductase, Trypanosoma cruzi, Leishmania, enzyme inhibitors, naphthoquinone, Microbiology, QR1-502, Infectious and parasitic diseases, RC109-216
Abstract

The enzyme trypanothione reductase is a recognised drug target in trypanosomatids and has been used in the search of new compounds with potential activity against diseases such as leishmaniasis, Chagas disease and African trypanosomiasis. 8-Methoxy-naphtho [2,3-b] thiophen-4,9-quinone was selected in a screening of natural and synthetic compounds using an in vitro assay with the recombinant enzyme from Trypanosoma cruzi. Its mode of inhibition fits a non-competitive model with respect to the substrate (trypanothione) and to the co-factor (NADPH), with Ki-values of 5 and 3.6 µM, respectively. When tested against human glutathione reductase, this compound did not display any significant inhibition at 100 µM, indicating a good selectivity against the parasite enzyme.

Published
2003

30. TrypanoCyc: a community-led biochemical pathways database for Trypanosoma brucei

Author

Shameer, Sanu, Logan-Klumpler, Flora J., Vinson, Florence, Cottret, Ludovic, Merlet, Benjamin, Achcar, Fiona, Boshart, Michael, Berriman, Matthew, Breitling, Rainer, Bringaud, Frédéric, Bütikofer, Peter, Cattanach, Amy M., Bannerman-Chukualim, Bridget, Creek, Darren J., Crouch, Kathryn, de Koning, Harry P., Denise, Hubert, Ebikeme, Charles, Fairlamb, Alan H., Ferguson, Michael A. J., Ginger, Michael L., Hertz-Fowler, Christiane, Kerkhoven, Eduard J., Mäser, Pascal, Michels, Paul A. M., Nayak, Archana, Nes, David W., Nolan, Derek P., Olsen, Christian, Silva-Franco, Fatima, Smith, Terry K., Taylor, Martin C., Tielens, Aloysius G. M., Urbaniak, Michael D., van Hellemond, Jaap J., Vincent, Isabel M., Wilkinson, Shane R., Wyllie, Susan, Opperdoes, Fred R., Barrett, Michael P., and Jourdan, Fabien

Published
2015
Full Text
View/download PDF

36. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness

Author

Frearson, Julie A., Brand, Stephen, McElroy, Stuart P., Cleghorn, Laura A.T., Smid, Ondrej, Stojanovski, Laste, Price, Helen P., Guther, M. Lucia S., Torrie, Leah S., Robinson, David A., Hallyburton, Irene, Mpamhanga, Chidochangu P., Brannigan, James A., Wilkinson, Anthony J., Hodgkinson, Michael, Hui, Raymond, Qiu, Wei, Raimi, Olawale G., van Aalten, Daan M.F., Brenk, Ruth, Gilbert, Ian H., Read, Kevin D., Fairlamb, Alan H., Ferguson, Michael A.J., Smith, Deborah F., and Wyatt, Paul G.

Subjects
Post-translational modification -- Research, Transferases -- Physiological aspects -- Control -- Research, Enzyme inhibitors -- Usage -- Health aspects, Trypanosomiasis -- Genetic aspects -- Care and treatment -- Research, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

African sleeping sickness or human African trypanosomiasis, caused by Trypanosoma bruceispp., is responsible for ~30,000 deaths each year. Available treatments for this disease are poor, with unacceptable efficacy and safety profiles, particularly in the late stage of the disease when the parasite has infected the central nervous system. Here we report the validation of a molecular target and the discovery of associated lead compounds with the potential to address this lack of suitable treatments. Inhibition of this target--T. brucei N-myristoyltransferase--leads to rapid killing of trypanosomes both in vitro and in vivo and cures trypanosomiasis in mice. These high-affinity inhibitors bind into the peptide substrate pocket of the enzyme and inhibit protein N-myristoylation in trypanosomes. The compounds identified have promising pharmaceutical properties and represent an opportunity to develop oral drugs to treat this devastating disease. Our studies validate T. brucei N-myristoyltransferase as a promising therapeutic target for human African trypanosomiasis., Protein N-myristoylation is a ubiquitous eukaryotic co- and posttranslational modification and is required for the membrane targeting and biological activity of many important proteins (1,2). The N-myristoylation reaction--the transfer of [...]

Published
2010
Full Text
View/download PDF

39. Characterisation of a putative glutamate 5‐kinase from Leishmania donovani

Author

Sienkiewicz, Natasha, Ong, Han B., and Fairlamb, Alan H.

Subjects
Proline, Genetic Vectors, Protozoan Proteins, Gene Expression, Glutamic Acid, drug target, Substrate Specificity, inhibitors, Escherichia coli, Humans, Protein Interaction Domains and Motifs, Amino Acid Sequence, Cloning, Molecular, biochemical pathway, Phylogeny, Leishmania, Aspartic Acid, Sequence Homology, Amino Acid, Genetic Complementation Test, Original Articles, Phosphotransferases (Carboxyl Group Acceptor), Recombinant Proteins, Kinetics, Biocatalysis, proline biosynthesis, Thermodynamics, Original Article, Protein Multimerization, Sequence Alignment, Leishmania donovani, Protein Binding
Abstract

Previous metabolic studies have demonstrated that leishmania parasites are able to synthesise proline from glutamic acid and threonine from aspartic acid. The first committed step in both biosynthetic pathways involves an amino acid kinase, either a glutamate 5‐kinase (G5K; http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/2/11.html) or an aspartokinase (http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/2/4.html). Bioinformatic analysis of multiple leishmania genomes identifies a single amino acid‐kinase gene (LdBPK 262740.1) variously annotated as either a putative glutamate or aspartate kinase. To establish the catalytic function of this Leishmania donovani gene product, we have determined the physical and kinetic properties of the recombinant enzyme purified from Escherichia coli. The findings indicate that the enzyme is a bona fide G5K with no activity as an aspartokinase. Tetrameric G5K displays kinetic behaviour similar to its bacterial orthologues and is allosterically regulated by proline, the end product of the pathway. The structure‐activity relationships of proline analogues as inhibitors are broadly similar to the bacterial enzyme. However, unlike G5K from E. coli, leishmania G5K lacks a C‐terminal PUA (pseudouridine synthase and archaeosine transglycosylase) domain and does not undergo higher oligomerisation in the presence of proline. Gene replacement studies are suggestive, but not conclusive that G5K is essential. Enzymes Glutamate 5‐kinase (http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/2/11.html); aspartokinase (http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/2/4.html).

Published
2018

42. Genome sequence of the human malaria parasite Plasmodium falciparum

Author

Gardner, Malcolm J., Hall, Neil, Fung, Eula, White, Owen, Berriman, Matthew, Hyman, Richard W., Carlton, Jane M., Pain, Arnab, Nelson, Karen E., Bowman, Sharen, Paulsen, Ian T., James, Keith, Eisen, Jonathan A., Rutherford, Kim, Salzberg, Steven L., Craig, Alister, Kyes, Sue, Chan, Man-Suen, Nene, Vishvanath, Shallom, Shamira J., Suh, Bernard, Peterson, Jeremy, Angiuoli, Sam, Pertea, Mihaela, Allen, Jonathan, Selengut, Jeremy, Haft, Daniel, Mather, Michael W., Vaidya, Akhil B., Martin, David M. A., Fairlamb, Alan H., Fraunholz, Martin J., Roos, David S., Ralph, Stuart A., McFadden, Geoffrey I., Cummings, Leda M., Subramanian, G. Mani, Mungall, Chris, Venter, J. Craig, Carucci, Daniel J., Hoffman, Stephen L., Newbold, Chris, Davis, Ronald W., Fraser, Claire M., and Barrell, Bart

Subjects
Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Author(s): Malcolm J. Gardner (corresponding author) [1]; Neil Hall [2]; Eula Fung [3]; Owen White [1]; Matthew Berriman [2]; Richard W. Hyman [3]; Jane M. Carlton [1]; Arnab Pain [2]; [...]

Published
2002
Full Text
View/download PDF

44. Discovery of an Allosteric Binding Site in Kinetoplastid Methionyl-tRNA Synthetase

Author

Torrie, Leah S., primary, Robinson, David A., additional, Thomas, Michael G., additional, Hobrath, Judith V., additional, Shepherd, Sharon M., additional, Post, John M., additional, Ko, Eun-Jung, additional, Ferreira, Rafael Alves, additional, Mackenzie, Claire J., additional, Wrobel, Karolina, additional, Edwards, Darren P., additional, Gilbert, Ian H., additional, Gray, David W., additional, Fairlamb, Alan H., additional, and De Rycker, Manu, additional

Published
2020
Full Text
View/download PDF

45. New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi

Author

Pedron, Julien, primary, Boudot, Clotilde, additional, Brossas, Jean-Yves, additional, Pinault, Emilie, additional, Bourgeade-Delmas, Sandra, additional, Sournia-Saquet, Alix, additional, Boutet-Robinet, Elisa, additional, Destere, Alexandre, additional, Tronnet, Antoine, additional, Bergé, Justine, additional, Bonduelle, Colin, additional, Deraeve, Céline, additional, Pratviel, Geneviève, additional, Stigliani, Jean-Luc, additional, Paris, Luc, additional, Mazier, Dominique, additional, Corvaisier, Sophie, additional, Since, Marc, additional, Malzert-Fréon, Aurélie, additional, Wyllie, Susan, additional, Milne, Rachel, additional, Fairlamb, Alan H., additional, Valentin, Alexis, additional, Courtioux, Bertrand, additional, and Verhaeghe, Pierre, additional

Published
2020
Full Text
View/download PDF

46. The Qi Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani

Author

Wall, Richard J., primary, Carvalho, Sandra, additional, Milne, Rachel, additional, Bueren-Calabuig, Juan A., additional, Moniz, Sonia, additional, Cantizani-Perez, Juan, additional, MacLean, Lorna, additional, Kessler, Albane, additional, Cotillo, Ignacio, additional, Sastry, Lalitha, additional, Manthri, Sujatha, additional, Patterson, Stephen, additional, Zuccotto, Fabio, additional, Thompson, Stephen, additional, Martin, Julio, additional, Marco, Maria, additional, Miles, Timothy J., additional, De Rycker, Manu, additional, Thomas, Michael G., additional, Fairlamb, Alan H., additional, Gilbert, Ian H., additional, and Wyllie, Susan, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results